TradingKey - On April 16, 2026, OpenAI released GPT-Rosalind, a large language model specifically designed for life sciences research. Initial users include pharmaceutical giant Amgen (AMGN), vaccine manufacturer Moderna (MRNA), and the Allen Institute. Following the announcement, the CRO sector saw a broad decline, with IQVIA Holdings (IQV) falling 3.5% and Charles River Laboratories (CRL) dropping 2.6%. Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR) both tumbled over 5% at one point.

TradingKeyFri, Apr 17

Revolution Medicines Doubles Pancreatic Cancer Survival in Phase 3 Trial — Is RVMD Stock a Buy at $136?

TradingKey - RVMD surged 41% after Phase 3 pancreatic cancer data doubled survival vs chemo. Analysts target $147–$165. Key support $125–$120. May 6 earnings next.

TradingKeyTue, Apr 14

Weight-Loss Drug Giant Eli Lilly Bets Big Again. Spending $7.8 Billion to Acquire Centessa, Is Now a Good Time to Buy Eli Lilly?

TradingKey - On March 31, Eastern Time, Eli Lilly officially announced its acquisition of U.S.-listed Centessa Pharmaceuticals for a total consideration of $7.8 billion, with the transaction expected to close in the third quarter of 2026. Following the news, Eli Lilly shares rose approximately 3% on Tuesday, while Centessa shares surged 45%.

TradingKeyWed, Apr 1

Chip stocks jump on AI optimism; Dow ends at record high

Cooling systems firms fall after Nvidia CEO's comments Memory and storage chipmakers hit record highs Stock valuations pricey ahead of earnings seasonS&P 500 +0.62%, Nasdaq +0.65%, Dow +0.99% By Noel Randewich Jan 6 (Reuters) - Wall Street ended higher on Tuesday, as chip stocks surged ...

ReutersWed, Jan 7

Novo Nordisk's New CEO Makes $5.2B Bet on Liver Disease Treatment Through Akero Acquisition

TradingKey - Danish pharmaceutical giant Novo Nordisk announced on Thursday that it will acquire U.S. biotechnology company Akero Therapeutics for a total consideration of up to $5.2 billion.

TradingKeyFri, Oct 10